G1 Therapeutics (NASDAQ:GTHX)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report issued on Wednesday, AnalystRatings.com reports. They currently have a $72.00 price objective on the stock. HC Wainwright’s target price would indicate a potential upside of 80.00% from the stock’s current price.
The analysts wrote, “We base our $72 price target on probability-adjusted revenue forecasts for trilaciclib in first line SCLC, second and third line SCLC, and metastatic TNB cancer plus lerociclib in ER+, HER2- breast cancer and EGFR mutant NSCLC. We use the net present value of our revenue forecast through 2026, apply a 50% and 40% POS for trilaciclib and lerociclib, respectively, a 3x price/sales multiple, and a $2.93/share value for the early stage pipeline that includes trilaciclib and lerociclib in other indications, and G1T48.””
Several other equities research analysts have also weighed in on the company. Cowen restated a “buy” rating on shares of G1 Therapeutics in a research report on Tuesday, June 18th. JPMorgan Chase & Co. upgraded G1 Therapeutics from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $38.00 to $45.00 in a report on Thursday, August 8th. ValuEngine raised G1 Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research cut shares of G1 Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 16th. Finally, BidaskClub raised shares of G1 Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, June 24th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $56.67.
Shares of GTHX opened at $40.00 on Wednesday. The company has a 50-day simple moving average of $32.15 and a two-hundred day simple moving average of $23.82. The firm has a market capitalization of $1.35 billion, a PE ratio of -15.63 and a beta of 2.35. G1 Therapeutics has a one year low of $13.87 and a one year high of $69.57.
G1 Therapeutics (NASDAQ:GTHX) last posted its earnings results on Wednesday, August 7th. The company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.09). Analysts anticipate that G1 Therapeutics will post -3.26 earnings per share for the current fiscal year.
A number of large investors have recently made changes to their positions in the business. Alps Advisors Inc. bought a new position in shares of G1 Therapeutics during the second quarter valued at $444,000. Chartwell Investment Partners LLC purchased a new stake in G1 Therapeutics during the 2nd quarter valued at about $1,538,000. Victory Capital Management Inc. bought a new stake in G1 Therapeutics during the 2nd quarter valued at about $889,000. Franklin Resources Inc. bought a new stake in shares of G1 Therapeutics during the second quarter valued at approximately $10,651,000. Finally, Laurion Capital Management LP bought a new stake in shares of G1 Therapeutics in the 2nd quarter worth $3,488,000. Institutional investors and hedge funds own 74.93% of the company’s stock.
About G1 Therapeutics
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.
Featured Story: Backdoor Roth IRA Conversion and Strategy
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.